Project Details
| Short title | 1397-0014 |
|---|---|
| Acronym | AIRTIVITY |
| Status | Active |
| Effective start/end date | 19/08/25 → 18/08/30 |
CTU: A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study)
- Morgan, Lucy (Primary Chief Investigator)
- Quinlan, Gabriel (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Garcia, Michelle (Clinical Trial Unit Staff)
- Armstrong, Emilia (Clinical Trial Unit Staff)
- Lawrie, Angus (Clinical Trial Unit Staff)
Project: Research